INTRODUCTION
Invasive aspergillosis (IA) is a major concern in hematology departments because of its high incidence and associated mortality. [1] [2] [3] The mortality rate usually exceeds 50% and can reach 90% in allogeneic hematopoietic stem cell transplantations recipients. 1, 4, 5 IA occurs mainly in immunosuppressed patients with prolonged neutropenia induced by chemotherapy and/or patients who undergo hematopoietic stem cell transplantation. 4, [6] [7] [8] IA prevention and treatment remain important issues.
Recently-observed improvement in survival 9 has been related to changes in clinical practices, and despite greater risk of aplasia, the prognosis of hematological diseases has improved in recent years with more efficient chemotherapies. 10 IA incidence varies according to underlying hematological disease and studies, ranking between 5 and 24% in acute leukemia patients [11] [12] [13] [14] and between 3% and 11% in allogeneic stem cell transplantation. [15] [16] [17] Medical prophylaxis with posaconazole [18] [19] and/or prevention strategies taking environmental factors into account [20] [21] could have contributed to a decrease in IA incidence. However, to the best of our knowledge, this IA incidence trend has not been described yet. On the other hand, hospital infection surveillance has been shown to be efficient in reducing infection rates. 22 Detailed reports on IA patient series are helpful in improving knowledge of the disease and potential changes of its natural history. Also, monitoring of recent trends and the clinical course of IA in hematology patients are topical in evaluating global medical support, 23 which may lead to the establishment of best-care strategies for patients at high risk of IA.
The objectives of this prospective survey-study were: 1) to estimate the incidence of IA according to underlying diagnosis, and 2) to describe the clinical and paraclinical characteristics of patients with IA in an hospital hematology department between 2004 and 2009.
DESIGN AND METHODS

Setting
Edouard Herriot Hospital is a 1,000-bed tertiary care institution composed of 32 blocks. One of these blocks accommodates the hematology department (42 beds), which is divided into 3 intensive care units. Two of these units contain 14 single rooms each, of which 8 rooms are equipped with laminar airflow (LAF), and 6 have no specific air treatment. The third unit was comprised of 10 conventional rooms, 4 with LAF until October 1, 2005, when it was relocated to an adjoining modular unit containing 14 rooms equipped with positive pressure isolation and HEPA filtration.
Study design and data sources
A prospective survey of IA cases was undertaken from January 1, 2004. A detailed description of this surveillance can be found elsewhere. 21 For the present study, the data were censored at December 31, 
Statistical analysis
Quantitative variables were described as number and percentage, and qualitative variables as median and interquartile range (IQR). IA incidence was calculated for 1,000 patients-days of hospitalization with 95% confidence interval (95% CI). To study temporal trends of IA incidence, Poisson regression was fitted with number of IA as the dependent variable, years of diagnosis as the independent variables and the number of patient-days at risk as an offset. All statistical tests were 2-tailed and P<0.05 was considered as statistically significant. . All data were analyzed anonymously with Stata 8.0 software (Stata Corp.). Our study received no external funding. According to French law, current surveillance of nosocomial infections in hospital and epidemiological observational surveys without any intervention do not need institutional review board authorization or written consent.
RESULTS
Participants
Overall, 4,073 hospitalized patients accounting for 78,360 patient-days at risk were included. The male/female sex ratio was 1.24 and median age was 51 years (IQR: 35.1-60.7 years). Totally, 2,078 (51%) patients were hospitalized for acute myeloid leukemia (AML) and 850 (21.9%) for acute lymphoid leukemia (ALL). One hundred and twenty-seven (3.1%) patients had IA. Among patient with IA 91 had AML and 19 had ALL, the IA incidence rates were respectively 4.4% and 2.2%
Invasive aspergillosis incidence
Overall incidence was 1.6 per 1,000 patient-days (95% CI: 1.4, 1.9) ( Figure 2 shows the relationship between the number of patients with aplasia and IA occurrence according to time period. It suggests an increase of IA incidence with aplasia.
Invasive aspergillosis patients
Mycological samples
A total of 127 samples were analyzed among 100 patients screened for mycological evidence. Thirtythree (26%) samples were positive for filamentous fungi on direct examination, 32 (25%) for culture, All-cause mortality was 13% (n=17) at 1 month and 42% (n=53) at 3 months after IA. All-cause mortality were respectively 14% (n=14) and 6% (n=1) among AML and ALL patients at 1 month, 38% (n=37) and 53% (n=9) at 3 months after IA. 9
DISCUSSION
The objectives were to report the incidence and clinical features of IA among hospitalized hematology patients. Knowledge of the clinical presentation of diseases is an important tool for sound clinical management. 23 Here, we detailed the clinical description of patients with IA in an hematology unit, based on a prospective survey system. IA incidence was 1.6 per 1,000 patient-days (95% CI: 1.4, 1.9), with a slightly linear decrease (15% per year) observed during the 2004-2009 study period.
To our knowledge, data on the IA incidence rate in hospitalized hematology patients are limited while cumulative incidence (i.e. attack rate) has been reported extensively in patients with various hematological diseases. 3, 4, 7, 14, [25] [26] [27] While IA increased in the 1980s-1990s in the general population, 2 no reduction of IA incidence has been observed in hematology patients. 3, 28 In our study, the decrease in .3% (P=.04), respectively. Also the absolute differences were 6.0% in the RCT 18 versus 1.6% in the present observational context. That pointed the differences of intervention according to the study design, RCT vs. observational data. Calibration of the trial, inclusion criteria, and standardization of measurements are cornerstone of RCT for increasing internal validity. In less favourable context such as observational design, we can expect a less strong effect of prophylaxis. 30 However, the difference was significant between the 2 periods. It is concordant with the study of Cornely and colleagues and it reinforce its conclusion. 18 Another explanation could be better control of environmental exposure (i.e. specially ventilated rooms) in the department. 21 Moreover, the decrease of IA incidence was most probably not due a lower incidence of Aspergillus antigen or a reduced number of positive CT scans. Indeed, Aspergillus antigen was usually researched 2 times a week in patient according to a local protocol. CT scans were performed after clinical suspicion and no major practice change was known.
The first signs suggesting IA appeared in 106 (84%) patients >10 days post-admission in the department. A cut-off of 7 days has often been recognized as an incubation period for fungal infections. 8 However, the incubation period preceding IA is still not known. According to our data, it can be argued that, in severely immunocompromised hosts with depletion of pulmonary conidia clearance, the incubation period ranges from 10 to 35 days. Thus, IA diagnosed before 10 days of hospitalization might be of undetermined origin, but could be related to early hospital exposure in severely immunocompromised patients. Another explanation might be that patients are colonized by Aspergillus and that chemotherapy or stem cell transplant facilitates invasive infection. Indeed, 5
patients had previous allogenic transplant, these cases of IA can be related to the second peak of IA which is usually observed in transplant recipients. Finally, if the time period for IA occurrence is ≥ 10 days, infection is probably hospital-acquired. It is clear from Figure 2 that the shape of IA case distribution differed after 10 days, indicating that different determinants could explain these 2 patterns of IA incidences.
We noted that 3-month all-cause mortality of 42% was much lower than in another study (64%). 31 It has been reported that 3-month mortality decreased from 45% in 1990-2001 to 22% in 2002-2004. 9 Moreover, Pagano et al. reported a 120 day overall mortality of 33% in AML patients with IA while the 3-month mortality was 38% in our cohort. 28 We observed a similar trend in a more recent period, which could be related to earlier diagnosis, more active antifungal drugs and/or changes in hematology practices. It has been suggested that late IA diagnosis could lead to poor prognosis. 32 In our study, continuous effort was made by the medical staff to diagnose IA as early as possible. Indeed, serum
Aspergillus antigen was tested 2 times/week during patient aplasia. Furthermore, lung CT-scans were taken ≤ 24 hours after clinical suspicion in most cases, reflecting the close attention paid by clinicians and radiologists to invasive fungal infections. Indeed, most lung CT-scans revealed the halo sign, which is usually seen early after onset. Our CT-scan findings were then comparable to those of Greene et al. 33 The incidence of halo signs and nodules without sign were 81% and 8%, respectively in our series. Greene reported incidences of 60.9% and 33.6%, respectively, in a broad sample of patients with IA. Our study cannot distinguish between the effects of improved chemotherapy or IA management on survival. However, it should be noted that acute leukemia patients and ideally other other hematologic malignancies should be closely evaluated and monitored to control the risk of IA.
High clinical suspicion that leads to early diagnosis might be considered by clinicians.
These results are encouraging and supported by some study strengths. Data were collected prospectively, on a standardized form, with multidisciplinary validation of IA cases by experts. Cases conformed to standardized international definitions. 24 The incidence trend was assessed in the entire patient cohort hospitalized during the study period, showing the actual IA incidence in hematology patients and adjusted for age and gender. However, some limitations must be mentioned. First, medical prophylaxis with posaconazole was not recorded in our surveillance system as this treatment was introduced for AML patients in induction chemotherapy during the year 2007. Second, external validity may be limited because the study was performed in a single institution. However, this weakness could be counterbalanced by the fact that the study included all patients of a typical hematology unit and no major changes occurred in diagnostic methods. Third, the study may have been underpowered, failing to show significant decreasing trends in IA mortality. In addition, limited data were available to adjust incidence trends with confounding factors such as aplasia, because this information was collected only for IA cases.
In summary, IA remains a frequent and highly lethal opportunistic infection in hematology patients despite a decrease in its incidence and probable mortality. Precise assessment of patient characteristics, clinical signs, and diagnostic tests as well as knowledge of IA clinical course would improve the management of these patients at high risk of infection. 6 Localizations are: cerebral and pulmonary (n=7); sinusitis and pulmonary (n=2); digestive and pulmonary (n=1); cutaneous and pulmonary (n=1); sinusitis, cerebral, cutaneous and pulmonary (n=1). 12/127 (9) NOTE: Data are numbers/number known (%) or specified otherwise. 1 Less than 500 neutrophils/mm 3 for >10 days. 2 Laminar air flow or positive pressure isolation, and high efficiency particulate filtration. 3 Persistent fever for >96 h refractory to appropriate antibiotic treatment. 4 ≥ 2 positive serum antigens against Aspergillus species. 5 Positive filamentous fungi and/or culture and/or Aspergillus antigen. 6 Localizations are: cerebral and pulmonary (n=7); sinusitis and pulmonary (n=2); digestive and pulmonary (n=1); cutaneous and pulmonary (n=1); sinusitis, cerebral, cutaneous and pulmonary (n=1). Delay between hospitalization and IA diagnosis 20 (13, 27) 19 (15, 31.5) 12 (7, 21) 20 (12, 27) Delay between aplasia and IA diagnosis 14 (10, 21) 13 ( 
